Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA flags risks from AbbVie, Gilead, Merck hepatitis C drugs to certain patients

The U.S. Food and Drug Administration identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co. Inc., Gilead Sciences Inc. and AbbVie Inc.

Read More »

Ionis licenses hepatitis B program to GSK

GlaxoSmithKline exercised an option to license Ionis Pharmaceuticals’ antisense medicines for people with chronic hepatitis B virus infection following positive Phase 2 results.

Read More »

Liver disease related to obesity and diabetes rising in U.S.

The only liver disease becoming more widespread in the U.S. is one driven by obesity and diabetes – NAFLD – even as other liver disorder types linked to drinking or hepatitis become less common.

Read More »

AbbVie’s Maviret approved by European Commission as shorter, 8-week, once-daily option

AbbVie announced that the European Commission granted marketing authorization for Maviret (glecaprevir/pibrentasvir) to shorten once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C patients with genotype 1, 2, 4, 5, and 6 infection.

Read More »

Durect and Gilead Collaborate on HIV Therapy

A collaboration and license deal was inked with Gilead Sciences Inc. to develop and market a long-acting injectable HIV therapy using Durect Corp.’s SABER technology.

Read More »

VBI hep B vaccine meets late-stage study’s main goals

VBI Vaccines Inc. said a late-stage study testing the company’s hepatitis B vaccine against GlaxoSmithKline’s Engerix-B met the main goals.

Read More »

Gilead to separate Kite cell therapy unit

Gilead Sciences Inc. said Kite Pharma Inc., the cancer-focused cell therapy company acquired in 2017, will become a separate business unit.

Read More »

AbbVie’s Mavyret Approved for Hep C in Pediatric and Adolescent Patients

The U.S. FDA approved AbbVie’s Mavyret for all six strains of hepatitis C in children ages 12 to 17 years. The drug was approved for adults 18 years or older during 2017.

Read More »

Gilead experimental NASH drug fails another study

Gilead Sciences Inc.’s experimental drug aimed at treating a type of fatty liver disease known as NASH failed to meet the main goal of a late-stage study, two months after failing another clinical trial.

Read More »

AbbVie’s 2018: Revenues Up, Earnings Down

AbbVie reported a loss of $1.83 billion for the fourth quarter of 2018. Overall revenues were up for full-year 2018, however, hitting $32.75 billion compared to $28.2 billion in 2017.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom